• locally advanced NSCLC - maintenance (M)
• laNSCLC - M - all population 1
• laNSCLC - M - EGFR mutant

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• durvalumab based treatment
• durvalumab alone

• versus all
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  laNSCLC - M - all population;